The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...

Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% during the ...

Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...